Literature DB >> 29026849

Increased Levels of VEGF-A and HIF-1α in Turkish Children with Crimean-Congo Hemorrhagic Fever.

Murat Sefikogullari1, Ali Kaya2, Huseyin Aydin3, Enver Sancakdar3, Veysel Kenan Celik3, Gokhan Bagci3.   

Abstract

BACKGROUND: Crimean-Congo Hemorrhagic Fever (CCHF) is a disease characterized by serious course, including acute viral fever, ecchymosis, thrombocytopenia, liver dysfunction and high rate of mortality. Hypoxia Inducible Factor-1α (HIF-1α) and Vascular Endothelial Growth Factor-A (VEGF-A) play an important role both in the inflammatory process and plasma leakage. The aim of this study was to define HIF-1α and VEGF-A serum levels obtained from CCHF patients and control group and to investigate whether these factors were correlated with the pathogenesis of this disease.
METHODS: Thirty cases younger than 17yr confirmed by RT-PCR and/or ELISA for CCHF were included in this study. Thirty age and sex matched healthy peoples were enrolled as controls. Blood samples collected from the patient and control groups. Serum levels of HIF-1α and VEGF-A were measured with ELISA.
RESULTS: Levels of HIF-1α and VEGF-A were statistically significantly increased in CCHF patients compared to the control group (P< 0.05). A significant positive correlation was found between the levels of HIF-1α and VEGF-A in the patient group (P< 0.01). The levels of ALT, AST, CK, aPTT, WBC and Thrombocyte count were significantly higher in the patients than in the control group (P< 0.001). A positive correlation was found among the levels of AST and CK from biochemical parameters and VEGF and HIF-1α in the patient group (P< 0.05).
CONCLUSION: HIF-1α and VEGF-A might play an important role in CCHF pathogenesis.

Entities:  

Keywords:  Children; Crimean congo hemorrhagic fever; HIF-1α; Sepsis; VEGF

Year:  2017        PMID: 29026849      PMCID: PMC5629302     

Source DB:  PubMed          Journal:  J Arthropod Borne Dis        ISSN: 2322-1984            Impact factor:   1.198


Introduction

Crimean-Congo Hemorrhagic Fever (CCHF) is a serious disease occurring in case of infection by tick-borne virus (Nairovirus) genus from Bunyaviridae family (Ergonul 2008). It begins with fever, severe headache, nausea, weakness, vomiting and progresses with bleeding in different parts of the body. “The bleeding findings emerge as subcutaneous bleeding, nasal bleeding, gingival bleeding and visceral bleeding” (Bakir et al. 2005). Mononuclear phagocytic cells, hepatocytes and endothelial cells are known as main target of CCHF virus (Whitehouse 2004, Ergonul et al. 2004). CCHF cases have been reported from more than 30 countries of Asia, South-Eastern Europe and Africa until now (Hubalek and Rudolf 2012). In Turkey, annually more than 1,000 human CCHF cases are reported (Maltezou et al. 2010). Like sepsis, endothelial damage plays an important role in the pathogenesis of CCHF. Endothelium may be indirectly targeted by virus mediated host derived soluble factors or directly by viral factors (Schnittler and Feldmann 2003). Hypoxia inducible factor (HIF-1α) is an oxygen sensitive transcription factor facilitating oxygen distribution and cellular adaptation to oxygen deprivation. HIF-1α activates transcription of genes, which encode angiogenic growth factors, including vascular endothelial growth factor (VEGF), angiopoietin 1 (ANGPT1), (ANGPT2), placental growth factor (PGF) and platelet-derived growth factor B (PDGFB), playing a critical role in angiogenesis. HIF-1α regulates expression of certain genes related with erythropoiesis, energy metabolism, angiogenesis, cell proliferation and apoptosis (Ferrara et al. 2003, Podar and Anderson 2005, Manalo et al. 2005). Vascular Endothelial Growth Factor (VEGF-A), a member of platelet-derived growth factors super family is specific for the endothelial cells and has important effects. Blood vessel formation is regulated mainly by vascular endothelial growth factor (VEGF-A) in health and disease. Human VEGF gene family consists of five members of VEGF A-E, among which VEGF-A is also commonly referred to as VEGF (Ferrara 2003). VEGF-A was also known as vascular permeability factor (VPF) due to its substantial effect on increasing of vascular permeability, resulting in a leakage out of blood vessels. One of the main aberrations in pathogenesis of CCHF is vascular dysfunction resulting in leakage driven hemorrhagic manifestations (Dvorak et al. 1995, Hoeben et al. 2004, Ergonul 2006). In this study, we aimed to demonstrate whether VEGF-A and HIF-1α was correlated with pathogenesis of sepsis in serum samples obtained from CCHF patients and control group.

Materials and Methods

Study design

Thirty patients diagnosed with CCHF in Department of Pediatrics, Faculty of Medicine, Cumhuriyet University, from 2010 to 2011 and 30 healthy controls were enrolled in the study. All of the patients with CCHF used to live in the same endemic region (Sivas and neighbor’s cities) which showed high prevalence in CCHF. Blood samples collected from the hospitalized patients with presumed diagnosis of CCHF were sent to Refik Saydam Hifzisihha Center, Virology Laboratory. Thirty patients having positive CCHFV RNA with Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) and/or positive CCHFV-specific IgM with ELISA were included in the study. Thirty age and sex matched healthy individuals who had not any infectious or metabolic diseases were enrolled as the controls. This study was approved by the Local Ethics Committee of Cumhuriyet University, Faculty of Medicine.

Measurement of HIF-1α and VEGF-A levels

Blood samples of 5 ml were collected from patient and control groups. The samples were centrifuged at 3000 rpm for 5 min and obtained serums were portioned and kept at −80 °C until the analysis time. Then these samples were cooled to the room temperature at the same time and HIF-1α and VEGF-A levels were measured through ELISA method. Human/Mouse Total HIF-1 alpha Cell-Based ELISA (R and D Systems, Inc.) and VEGF-A Human (BioVendor) kits were used to measure the levels of HIF-1α and VEGF-A. MicroELISA (sandwich) method was performed using full automatic TRITURUS device.

Statistical analysis

All statistical analyses were conducted with IBM SPSS Statistics for Windows, Version 20.0 (Chicago, IL, USA) computer program. Descriptive statistics were expressed as arithmetic mean (min-max). Mann–Whitney U test was performed to determine the significance of independent continuous variables. For bivariate correlation analysis, Pearson’s or Spearman’s test was used. In evaluation of the categorical data, Chi-square test was used in the statistical analyses. P< 0.05 values were considered as statistically significant for all the tests.

Results

Demographic features and laboratory findings of the controls and patient groups are given in Table 1. Mean age was found as 11.30±4.41 in the patients and 10.40±4.49 in the controls. Nineteen of the patients were male (63.3%) and 11 were female (36.7%), whereas 20 (66.7%) of the controls were male and 10 (33.3%) were female. The differences between the controls and patient groups in terms of age and gender were not significant.
Table 1.

Comparison of demographic and laboratory findings of the patients and controls

VariableControl (n=30)CCHF (n=30)P
Age (mean±SD)10.40±4.4911.30±4.410.05
Age range2–172–170.05
Male (%)20 (66.7%)19 (63.3%)0.05
Female (%)20 (66.7%)19 (63.3%)0.05
ALT (IU/L)35 (12–48)83 (28–335)<0.001
AST (IU/L)38 (11–54)171 (26–357)<0.001
CK (IU/L)107 (68–172)899 (140–1235)<0.001
Prothrombin time (s)14.4 (9.6–14.0)15.9 (9.6–20.1)>0.05
aPTT (s)34.7 (13.5–45.7)42.4 (23.8–55.1)0.022
INR1.2 (0.8–2.2)1.3 (0.9–2.4)>0.05
WBC (×109 cells/L)5.7 (3.5–7.0)3.17 (1.2–9.0)<0.05
Hemoglobin (g/dL)14.2 (8.3–15.8)13.6 (11.8–15.8)>0.05
Thrombocyte count (×103 cells/L)176 (69–214)110 (38–152)<0.001

ALT: Alanine aminotransferase

AST: Aspartate aminotransferase

CK: Creatine kinase

aPTT: activated partial thromboplastin time

INR: International normalized ratio

WBC: White blood cell

Comparison of demographic and laboratory findings of the patients and controls ALT: Alanine aminotransferase AST: Aspartate aminotransferase CK: Creatine kinase aPTT: activated partial thromboplastin time INR: International normalized ratio WBC: White blood cell A statistically significant increase was observed in the levels of HIF-1α and VEGF in the patients compared to control groups (P< 0.05, Table 2). A significant positive correlation was found between the levels of HIF-1α and VEGF-A in patient group (P< 0.01, Table 2). A positive correlation was found among the levels of AST and CK from biochemical parameters and VEGF and HIF-1α (P< 0.05), while this was not significant in ALT (P= 0.086, Table 3).
Table 2.

Serum levels of VEGF-A and HIF-1α in the patient and control groups

PatientsControlP
VEGF-A (pg/ml)312.66±87.31150.70±78.480.001
HIF-1α (pg/ml)195.93±63.4968.20±36.110.001
Table 3.

HIF-1α and VEGF-A correlation between biochemical parameters in patients with CCHF

VariableHIF-1αVEGF-A

Correlation CoefficientPCorrelation CoefficientP
ALT0.1810.0860.1620.103
AST0.2560.0200.2660.022
CK0.2140.0120.2920.048
VEGF-A0.969<0.01--

ALT: Alanine aminotransferase

AST: Aspartate aminotransferase

CK: Creatine kinase

Serum levels of VEGF-A and HIF-1α in the patient and control groups HIF-1α and VEGF-A correlation between biochemical parameters in patients with CCHF ALT: Alanine aminotransferase AST: Aspartate aminotransferase CK: Creatine kinase The levels of ALT, AST and CK were statistically significantly higher in CCHF patients than in the control group (P< 0.001). There was a significant increase in the levels of aPTT in coagulation tests compared to controls (P=0.022), increase in the prothrombin time and INR was not statistically significant (P> 0.05 Table 1). WBC (P< 0.05) and thrombocyte counts (P< 0.001) were statistically lower in the patients than in the control group, while no significant difference was observed in the amount of hemoglobin.

Discussion

We aimed to demonstrate whether HIF-1α and VEGF, related to sepsis and viral infection, were correlated with pathogenesis of CCHF disease. Despite numerous studies conducted about CCHF, pathogenesis of the disease is not fully understood. There was a relationship between sepsis and viral infection, and HIF-1α and VEGF (Irwin et al. 2009). In infected humans by the CCHFV, damaging of endothelial cells and vascular leakage may be a direct result of an immune mediated indirect effect (Schnittler and Feldmann 2003). A common characteristic of viral hemorrhagic fevers is viruses to enter macrophages and dendritic cells, making a cytopathic effect. VEGF produced by monocytes and endothelial cells is known to play an important role in breakdown of coagulation, leukocyte adhesion, angiogenesis and increased vascular permeability (Burt et al. 1997, Geisbert and Jahrling 2004). It is known as a deteriorated coagulation, leukocyte adhesion, angiogenesis and increased vascular permeability in CCHF patients (Bodur et al. 2010). Clinical symptoms of CCHF are similar to sepsis and endothelial structure of vessels is retrograded (Elson et al. 2001). The correlation of sepsis and viral infection with HIF-1α and VEGF-A was shown (Kilani et al. 2004, Zinkernagel et al. 2007). At hypoxic conditions, hypoxia-inducible factor (HIF) regulates expression of certain genes. In in vivo and in vitro studies, oxygen tension affects virus production either up regulating or down regulating viral replication depending on virus type and method used for to study viral replication. Viral replication is modulated mainly by HIF-1α in normal and hypoxic conditions (Morinet et al. 2013). HIF-1α is known to activate transcription of the genes including VEGF and other angiogenic growth factors and plays a critical role in the development of angiogenesis in hypoxic conditions (Manalo et al. 2005). HIF-1α mRNA expression was suppressed and conversely associated with disease severity in sepsis (Schaefer et al. 2013). HIF-1α expression was statistically significantly higher in the shock patients compared to the controls and the reasons of shock were sepsis (78%), hemorrhage (18%), and cardiac dysfunction (4%) (Textoris et al. 2012). In sepsis, microvascular permeability closely associates with the increased plasma VEGF concentration (Pickkers et al. 2005). ROS–HIF-1α–VEGF pathway is partly responsible for hypoxia-induced permeability (Irwin et al. 2009). The levels of VEGF increased in sepsis, and this increase correlated with severity of the disease and mortality (van der Flier et al. 2005, Yano et al. 2006, Karlsson et al. 2008). Inhibition of VEGF signaling contributes the development of sepsis-induced organ dysfunction via blocking endothelial survival and increasing apoptosis. Furthermore, in pathological situations like sepsis and cancer, VEGF participates to mobilizing of endothelial progenitor cells (Jesmin et al. 2012). The main target of sepsis-induced events is generally endothelium, so ability to ameliorate damaged endothelium is one of the main determiners of clinical outcome in septic patients. The angiogenic factors and their soluble receptors have a dual role and seem to play both beneficial and harmful effects during sepsis development and therapy. While normal levels of VEGF is required for protection of endothelial function, both extremely high or low levels of VEGF have disruptive effect on endothelial barrier (Zhang et al. 2013). In our study, a strong correlation was seen between the levels of HIF-1α and VEGF-A in CCHF patients (Table 3). Besides, a positive correlation was found between HIF-1α and VEGF-A, suggesting that angiogenesis could be triggered and, pathogenesis of the disease could be influenced. Accordingly, we recommend that comprehensive studies related to angiogenesis should be conducted in CCHF patients. Despite the absence of studies that investigated HIF-1α levels in patients with CCHF in the literature, the studies that evaluating VEGF levels have increased in recent years. All of the studies that investigate serum levels of VEGF have been conducted with Turkish CCHF patients. Serum levels of VEGF was statistically higher in the adult patients having CCHF compared to the controls (Bakir et al. 2013), and in another study, levels of VEGF was found statistically higher in fatal CCHF patients compared to the non-fatal patients (Ozturk et al. 2010). In contrast to these findings, level of VEGF was significantly decreased in CCHF patients (Bodur et al. 2010). Our study was not consistent with the study by Bodur et al. while it was consistent with the other two studies. In studies conducted with other hemorrhagic fevers such as dengue hemorrhagic fever (DHF) (Tseng et al. 2000, Srikiatkhachorn et al. 2007, Furuta et al. 2012, del Moral-Hernández et al. 2014) and hemorrhagic fever with renal syndrome (HFRS) (Ma et al. 2012), also VEGF level was statistically significantly higher in patient groups. Consequently, all of these studies indicate that VEGF regulates vascular permeability and VEGF is a good marker of the severity of the infection by viral diseases such as CCHF and DHF. Our study has some limitations. First, we could not linked the levels of HIF-1α and VEGF-A together with disease severity. Second, HIF-1α and VEGF-A serum levels were not compared between patients with survival and non-survival. Lastly, we did not evaluate the levels of VEGF-A and HIF-1α in another viral disease -especially the other hemorrhagic fevers- or patients with sepsis. Increased levels of the HIF-1α which is the main transcriptional factor of the regulation of oxygen homeostasis and VEGF-A which has a crucial role in the regulation of angiogenesis and vascular permeability suggested that these parameters might contribute to the development of vascular endothelial damage. Nevertheless, because of the insufficient information about molecular mechanism on pathogenesis of CCHF, our results indicate that VEGF and HIF-1α should be one of the markers need to be focused on the elucidation on the pathogenesis of CCHF disease.

Conclusion

Significant higher levels of HIF-1α and VEGF-A in the CCHF patients than in controls, suggested that HIF-1α and VEGF-A expression might be effective on the pathogenesis of CCHF patients, especially on the occurrence of endothelial damage and disruption of coagulation. Combined use of HIF-1α inhibitors with antiviral agents may be useful for the treatment of CCHF patients. Further comprehensive studies on this issue are recommended.
  36 in total

Review 1.  Exotic emerging viral diseases: progress and challenges.

Authors:  Thomas W Geisbert; Peter B Jahrling
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

2.  Association DENV1 and DENV2 infection with high serum levels of soluble thrombomodulin and VEGF in patients with dengue fever and dengue hemorrhagic fever.

Authors:  Oscar Del Moral-Hernández; Norma E Martínez-Hernández; Manuel A Mosso-Pani; Daniel Hernández-Sotelo; Berenice Illades-Aguiar; Eugenia Flores-Alfaro; Verónica Antonio-Vejar; Marco Antonio Leyva-Vázquez
Journal:  Int J Clin Exp Med       Date:  2014-02-15

Review 3.  Crimean-Congo hemorrhagic fever.

Authors:  Chris A Whitehouse
Journal:  Antiviral Res       Date:  2004-12       Impact factor: 5.970

4.  Evaluation of the association of serum levels of hyaluronic acid, sICAM-1, sVCAM-1, and VEGF-A with mortality and prognosis in patients with Crimean-Congo hemorrhagic fever.

Authors:  Baris Ozturk; Ferit Kuscu; Ediz Tutuncu; Irfan Sencan; Yunus Gurbuz; Hakan Tuzun
Journal:  J Clin Virol       Date:  2009-12-11       Impact factor: 3.168

Review 5.  Hypoxia inducible factor (HIF) function in innate immunity and infection.

Authors:  Annelies S Zinkernagel; Randall S Johnson; Victor Nizet
Journal:  J Mol Med (Berl)       Date:  2007-11-21       Impact factor: 4.599

6.  Vascular endothelial growth factor in severe sepsis and septic shock.

Authors:  Sari Karlsson; Ville Pettilä; Jyrki Tenhunen; Vesa Lund; Seppo Hovilehto; Esko Ruokonen
Journal:  Anesth Analg       Date:  2008-06       Impact factor: 5.108

7.  Hypoxia-inducible factor (HIF1α) gene expression in human shock states.

Authors:  Julien Textoris; Nathalie Beaufils; Gabrielle Quintana; Amin Ben Lassoued; Laurent Zieleskiewicz; Sandrine Wiramus; Valéry Blasco; Nathalie Lesavre; Claude Martin; Jean Gabert; Marc Leone
Journal:  Crit Care       Date:  2012-07-10       Impact factor: 9.097

8.  Association of mast cell-derived VEGF and proteases in Dengue shock syndrome.

Authors:  Takahisa Furuta; Lyre Anni Murao; Nguyen Thi Phuong Lan; Nguyen Tien Huy; Vu Thi Que Huong; Tran Thi Thuy; Vo Dinh Tham; Cao Thi Phi Nga; Tran Thi Ngoc Ha; Yasukazu Ohmoto; Mihoko Kikuchi; Kouichi Morita; Michio Yasunami; Kenji Hirayama; Naohiro Watanabe
Journal:  PLoS Negl Trop Dis       Date:  2012-02-21

9.  Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality.

Authors:  Kiichiro Yano; Patricia C Liaw; Janet M Mullington; Shu-Ching Shih; Hitomi Okada; Natalya Bodyak; Peter M Kang; Lisa Toltl; Bryan Belikoff; Jon Buras; Benjamin T Simms; Joseph P Mizgerd; Peter Carmeliet; S Ananth Karumanchi; William C Aird
Journal:  J Exp Med       Date:  2006-05-15       Impact factor: 14.307

Review 10.  Crimean-Congo haemorrhagic fever.

Authors:  Onder Ergönül
Journal:  Lancet Infect Dis       Date:  2006-04       Impact factor: 25.071

View more
  3 in total

1.  Coordinated expression of vascular endothelial growth factor A and urokinase-type plasminogen activator contributes to classical swine fever virus Shimen infection in macrophages.

Authors:  Xiaocheng Gong; Aoxue Hu; Xuepeng Li; Jun He; Zhongxing Wu; Xi Zuo; Pengbo Ning
Journal:  BMC Vet Res       Date:  2019-03-08       Impact factor: 2.741

2.  AIP1 suppresses neovascularization by inhibiting the NOX4-induced NLRP3/NLRP6 imbalance in a murine corneal alkali burn model.

Authors:  Qingyu Li; Xia Hua; Liangpin Li; Xueyan Zhou; Ye Tian; Yang Deng; Min Zhang; Xiaoyong Yuan; Wei Chi
Journal:  Cell Commun Signal       Date:  2022-05-06       Impact factor: 7.525

3.  Crimean-Congo hemorrhagic fever virus strains Hoti and Afghanistan cause viremia and mild clinical disease in cynomolgus monkeys.

Authors:  Robert W Cross; Abhishek N Prasad; Viktoriya Borisevich; Joan B Geisbert; Krystle N Agans; Daniel J Deer; Karla A Fenton; Thomas W Geisbert
Journal:  PLoS Negl Trop Dis       Date:  2020-08-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.